Clinical Trial Update: Sunitinib Malate in Refractory Germ Cell Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial of sunitinib malate in patients with refractory germ cell tumors was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor
• Testicular Germ Cell Tumor

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Genitourinary Disease | Phase 2 | Status: TERMINATED | Results posted: 2016-01-27